Anti-NET antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository.
Yu ZuoSherwin NavazAlex TsodikovKatarína KmeťováLyndsay KlugeAmala AmbatiClaire K HoySrilakshmi YalavarthiDanieli de AndradeMaria G G TektonidouSavinio SciasciaVittorio PengoGuillermo Ruiz-IrastorzaH Michael BelmontMaria GerosaPaul R FortinGuilherme Ribeiro Ramires de JésusD Ware BranchLaura AndreoliEsther Rodriguez-AlmarazMichelle A PetriRicard CerveraRohan WillisEdward M BehrensQuan-Zhen LiHannah CohenMaria Laura BertolacciniDoruk ErkanChristian Loodnull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
These data reveal high levels of anti-NET antibodies in 45% of aPL-positive patients, where they potentially activate the complement cascade. While anti-NET IgM may especially recognize DNA in NETs, anti-NET IgG species appear more likely to target NET-associated protein antigens. This article is protected by copyright. All rights reserved.
Keyphrases
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- emergency department
- systemic lupus erythematosus
- randomized controlled trial
- dendritic cells
- artificial intelligence
- dna methylation
- cell free
- immune response
- circulating tumor
- electronic health record
- genetic diversity
- double blind
- phase iii